Clinical Trial Update: An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

This is an open-label Phase II study assessing the efficacy and safety of sunitinib (Sutent) in patients with hormone-refractory prostate cancer. The trial stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Prostatic Neoplasms, Neoplasms, Hormone-Dependent | Phase 2 | Status: COMPLETED